Impact of Cell Composition and Geometry on Human Induced Pluripotent Stem Cells-Derived Engineered Cardiac Tissue

Scientific Reports

Volumn 7, Issue , 2017, Pages

  Nakane, Takeichiro ^a,b,c   Masumoto, Hidetoshi ^a,b,c   Tinney, Joseph P ^a,d   Yuan, Fangping ^a,d   Kowalski, William J ^a,d   Ye, Fei ^a,d   Leblanc, Amanda J ^d   Sakata, Ryuzo ^c   Yamashita, Jun K ^b   Keller, Bradley B ^a,d  

^a UNIVERSITY OF LOUISVILLE   (United States)

^b KYOTO UNIVERSITY   (Japan)

^c KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^d University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; CYTOLOGY; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; INDUCED PLURIPOTENT STEM CELL; MALE; NUDE RAT; PATHOPHYSIOLOGY; PROCEDURES; REGENERATION; TISSUE ENGINEERING; TRANSPLANTATION; XENOGRAFT;

ANIMALS; CELL COUNT; CELL DIFFERENTIATION; CELL SURVIVAL; HUMANS; INDUCED PLURIPOTENT STEM CELLS; MALE; MYOCARDIAL INFARCTION; MYOCARDIUM; MYOCYTES, CARDIAC; RATS, NUDE; REGENERATION; TISSUE ENGINEERING; TRANSPLANTATION, HETEROLOGOUS; VENTRICULAR REMODELING;

EID: 85016951942     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep45641     Document Type: Article

References (36)

1. Mozafarian, D. et al. Heart Disease and Stroke Statistics-2016 Update: A Report From the American Heart Association. Circulation, doi: 10.1161/CIR.0000000000000350 (2015).
2. Bolli, R. et al. Cardiac stem cells in patients with ischaemic cardiomyopathy (SCIPIO): initial results of a randomised phase 1 trial. Lancet 378, 1847-1857 (2011).
3. Sanganalmath, S. K. & Bolli, R. Cell therapy for heart failure: A comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ. Res. 113, 810-834 (2013).
4. Masumoto, H. et al. Human iPS cell-engineered cardiac tissue sheets with cardiomyocytes and vascular cells for cardiac regeneration. Sci. Rep. 4, 6716 (2014).
5. Chong, J. J. H. et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510, 273-277 (2014).
6. Fisher, S. A., Doree, C., Mathur, A. & Martin-Rendon, E. Meta-Analysis of Cell Terapy Trials for Patients With Heart Failure. Circ. Res. 116, 1361-1377 (2015).
7. Menasché, P. et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: frst clinical case report. Eur. Heart J. 36, 2011-2017 (2015).
8. Masumoto, H. et al. The myocardial regenerative potential of three-dimensional engineered cardiac tissues composed of multiple human iPS cell-derived cardiovascular cell lineages. Sci. Rep. 6, 29933 (2016).
9. Marín-García, J. Cell death in the pathogenesis and progression of heart failure. Heart Fail. Rev. 21, 117-121 (2016).
10. Takahashi, K. et al. Induction of pluripotent stem cells from adult human fbroblasts by defned factors. Cell 131, 861-72 (2007).
11. Yamashita, J. K. ES and iPS cell research for cardiovascular regeneration. Exp. Cell Res. 316, 2555-2559 (2010).
12. Lalit, P. A., Hei, D. J., Raval, A. N. & Kamp, T. J. Induced Pluripotent Stem Cells for Post-Myocardial Infarction Repair: Remarkable Opportunities and Challenges. Circ. Res. 114, 1328-1345 (2014).
13. Zimmermann, W.-H. et al. Engineered heart tissue grafs improve systolic and diastolic function in infarcted rat hearts. Nat. Med. 12, 452-458 (2006).
14. Tulloch, N. L. et al. Growth of Engineered Human Myocardium With Mechanical Loading and Vascular Coculture. Circ. Res. 109, 47-59 (2011).
15. Schaaf, S. et al. Human engineered heart tissue as a versatile tool in basic research and preclinical toxicology. PLoS One 6 (2011).
16. Riegler, J. et al. Human Engineered Heart Muscles Engraf and Survive Long Term in a Rodent Myocardial Infarction Model. Circ. Res. 117, 720-730 (2015).
17. Weinberger, F. et al. Cardiac repair in guinea pigs with human engineered heart tissue from induced pluripotent stem cells. Sci. Transl. Med. 8, 363ra148-363ra148 (2016).
18. Tobita, K. et al. Engineered early embryonic cardiac tissue retains proliferative and contractile properties of developing embryonic myocardium. Am. J. Physiol. Heart Circ. Physiol. 291, H1829-37 (2006).
19. Fujimoto, K. L. et al. Engineered fetal cardiac graf preserves its cardiomyocyte proliferation within postinfarcted myocardium and sustains cardiac function. Tissue Eng. Part A 17, 585-96 (2011).
20. Sakaguchi, K. et al. In vitro engineering of vascularized tissue surrogates. Sci. Rep. 3, 1316 (2013).
21. Sun, X., Altalhi, W. & Nunes, S. S. Vascularization strategies of engineered tissues and their application in cardiac regeneration. Adv. Drug Deliv. Rev., doi: 10.1016/j.addr.2015.06.001 (2015).
22. Matsuo, T. et al. Efcient long-term survival of cell grafs afer myocardial infarction with thick viable cardiac tissue entirely from pluripotent stem cells. Sci. Rep. 5, 16842 (2015).
23. Perea-Gil, I., Prat-Vidal, C. & Bayes-Genis, A. In vivo experience with natural scafolds for myocardial infarction: the times they are a-changin'. Stem Cell Res. Ter. 6, 248 (2015).
24. Gaetani, R. et al. Cardiac tissue engineering using tissue printing technology and human cardiac progenitor cells. Biomaterials 33, 1782-1790 (2012).
25. Bian, W., Liau, B., Badie, N. & Bursac, N. Mesoscopic hydrogel molding to control the 3D geometry of bioartifcial muscle tissues. Nat. Protoc. 4, 1522-34 (2009).
26. Zhang, D. et al. Tissue-engineered cardiac patch for advanced functional maturation of human ESC-derived cardiomyocytes. Biomaterials 34, 5813-20 (2013).
27. Christoforou, N. et al. Induced pluripotent stem cell-derived cardiac progenitors differentiate to cardiomyocytes and form biosynthetic tissues. PLoS One 8, e65963 (2013).
28. Mannhardt, I. et al. Human Engineered Heart Tissue: Analysis of Contractile Force. Stem Cell Reports 7, 29-42 (2016).
29. Me, C. Developmental Changes in Cardiomyocytes Differentiated from Human Embryonic Stem Cells: A Molecular and Electrophysiological Approach. 1136-1144, doi: 10.1634/stemcells.2006-0466 (2007).
30. Tang, X. L. et al. Intracoronary administration of cardiac progenitor cells alleviates lef ventricular dysfunction in rats with a 30-day-old infarction. Circulation 121, 293-305 (2010).
31. Ozerdem, U., Grako, K. A., Dahlin-Huppe, K., Monosov, E. & Stallcup, W. B. NG2 proteoglycan is expressed exclusively by mural cells during vascular morphogenesis. Dev. Dyn. 222, 218-227 (2001).
32. Chen, W. C. W. et al. Human myocardial pericytes: Multipotent mesodermal precursors exhibiting cardiac specifcity. Stem Cells 33, 557-573 (2015).
33. Eder, A. et al. Effects of proarrhythmic drugs on relaxation time and beating pattern in rat engineered heart tissue. Basic Res. Cardiol. 109 (2014).
34. Endoh, M. Force-frequency relationship in intact mammalian ventricular myocardium: Physiological and pathophysiological relevance. Eur. J. Pharmacol. 500, 73-86 (2004).
35. Uosaki, H. et al. Efcient and Scalable Purifcation of Cardiomyocytes from Human Embryonic and Induced Pluripotent Stem Cells by VCAM1 Surface Expression. PLoS One 6, e23657 (2011).
36. Bauer, M. et al. Echocardiographic speckle-tracking based strain imaging for rapid cardiovascular phenotyping in mice. Circ. Res. 108, 908-916 (2011).